Lifescience-online : the global ressource for pharma and biotech business
| BIOFINANCIAL
NEWS
|
 | Tue, 12:00 (GMT+1)
|
| Related information
|
|
| PIPELINE
NEWS
|
 | Wed, 12:00 (GMT+1)
|
| Related information
|
|
|
| FROM OUR EDITORS |
 |
The practice of raising large amounts of money in Switzerland shows that Swiss and foreign companies appreciate the outstanding market environment in Switzerland and at SWX.
|
 |
Medical therapies are being driven to reduce hospital costs by administering treatments at home or even on the go. This demand has launched new generations of portable devices...
|
|
 |
Monoclonal antibodies represent one of the most innovative and promising therapeutic approaches of the last two decades.
|
 |
In the USA, it is estimated that 1.5 million Americans have Parkinson's disease and 60,000 new
cases are diagnosed each year. Moreover, 30,000 Americans suffer from Amyotrophic Lateral Sclerosis,
with 5,600 new cases diagnosed each year. Finally, one out of every 10,000 Americans has Huntington's Disease.
Concomitantly, these numbers underline why there is a huge potential for treatments.
|
|
| RECENT DEALS |
| July 1st, 2008, Palatin Technologies announced that AstraZeneca and Palatin have amended their exclusive global licensing and research collaboration agreement to discover, develop and commercialize compounds that target melanocortin receptors.
|
| June 25th, 2008, Melior Discovery announced that it had signed an option agreement that provides Pfizer the exclusive right to negotiate a license to MLR-1023. In exchange, Pfizer agreed to make an undisclosed payment to Melior and provide access to certain data it owns related to MLR-1023. In addition, Melior agreed to utilize its in-vivo theraTRACE® indications discovery platform to evaluate the activity of selected Pfizer compounds in partnership with Pfizer.
|
| May 25th, 2006, Isotechnika signed an agreement with Lux Biosciences granting Lux worldwide rights to develop and commercialize Isotechnika's lead drug, voclosporin (LX-211) for the treatment and prophylaxis of all ophthalmic diseases. |
|
More Alliances & Partnerships: Key Players | Start Ups |
|
